Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Inhibition of dipeptidyl peptidase-4 (DPP-4) as a novel therapy for type 2 diabetes is based on prevention of the inactivation process of bioactive peptides, the most important in the context of treatment of diabetes of which is glucagon-like peptide-1 (GLP-1). Most clinical experience with DPP-4 inhibition is based on vildagliptin (GalvusR, Novartis) and sitagliptin (JanuviaR, Merck). These compounds improve glycemic control both in monotherapy and in combination with other oral hyperglycemic agents. Both have also been shown to efficiently improve glycemic control when added to ongoing metformin therapy in patients with inadequate glycemic control. Under that condition, they reduce HbA1C levels by 0.65%-1.1% (baseline HbA1C 7.2-8.7%) in studies up to 52 weeks of duration in combination versus continuous therapy with metformin alone. Sitagliptin has also been examined in initial combination therapy with metformin have; HbA1 was reduced by this combination by 2.1% (baseline HbA1C 8.8%) after 24 weeks of treatment. Both fasting and prandial glucose are reduced by DPP-4 inhibition in combination with metformin in association with improvement of insulin secretion and insulin resistance and increase in concentrations of active GLP-1. The combination of DPP-4 inhibition and metformin has been shown to be highly tolerable with very low risk of hypoglycemia. Hence, DPP-4 inhibition in combination with metformin is an efficient, safe and tolerable combination therapy for type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Katz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G., & Quon, M. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6661 · Cited by 3,931
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 3×
“The two most important incretin hormones are glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) (Drucker and Nauck 2006).”
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Pathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148 · cited 3×
“Metformin reduces glycemic levels primarily by inhibiting hepatic glucose output (Bailey and Turner 1996; Leverve et al 2003; Stumvoll et al 1995).”
Charbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group (2006) · Diabetes Care · doi:10.2337/dc06-0706 · Cited by 790
Raz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D., Khatami, H., & Sitagliptin Study 023 Group (2006) · Diabetologia · doi:10.1007/s00125-006-0416-z · Cited by 614
T., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518 · cited 1×
“However, since the action of GIP to stimulate insulin secretion is almost entirely lost in type 2 diabetes (Vilsbøll et al 2002), this raise of GIP concentrations is of less importance.”
Goldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., & for the Sitagliptin 036 Study Group (2007) · Diabetes Care · doi:10.2337/dc07-0627 · Cited by 509
Ahrén, B., Gomis, R., Standl, E., Mills, D., & Schweizer, A. (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2874 · Cited by 487
Ahrén, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.-A., Sandqvist, M., Båvenholm, P., Efendic, S., Eriksson, J. W., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.869 · Cited by 421 · cited 1×
“The fi rst proof-of-concept study of DPP-4 inhibition showed improved meta bolic control with reduced fasting and prandial glucose levels and reduction of HbA 1c after 4 weeks of treatment of the DPP-4 inhibitor, NVP-DPP728 (Ahrén et al 2002).”
Mannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Mencucci, A., Pierazzuoli, E., Ciani, S., Messeri, G., & Rotella, C. M. (2001) · Diabetes Care · doi:10.2337/diacare.24.3.489 · Cited by 300 · cited 3×
“…mechanism underlying the increase in GLP-1 levels by metformin remains to be fi nally established; it has been suggested to be caused by inhibition of DPP-4 (Lindsay et al 2005; Mannucci et al 2001), although there are also fi ndings that metformin does not affect DPP-4 activity (Hinke et al 2002).”
Rosenstock, J., Kim, S. W., Baron, M. A., Camisasca, R. ‐., Cressier, F., Couturier, A., & Dejager, S. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00698.x · Cited by 255 · cited 4×
“In contrast to GLP-1, DPP-4 inhibi tion does not seem to inhibit gastric emptying (Vella et al 2007) and it does not reduce body weight (Ahrén et al 2004b; Aschner et al 2006; Pratley et al 2006; Raz et al 2006; Ristic et al 2005; Rosenstock et al 2007; Schweizer et al 2007; Scott et al 2007).”
InfluentialCharbonnel, B., Schernthaner, G., Brunetti, P., Matthews, D. R., Urquhart, R., Tan, M. H., & Hanefeld, M. (2005) · Diabetologia · doi:10.1007/s00125-005-1751-1 · Cited by 170
The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes
Donnelly, L. A., Doney, A. S. F., Hattersley, A. T., Morris, A. D., & Pearson, E. R. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01755.x · Cited by 88
Cited by
Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes
Ahrén, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2782 · Cited by 419
Treatment strategies against diabetes: Success so far and challenges ahead.
Khursheed, R., Singh, S. K., Wadhwa, S., Kapoor, B., Gulati, M., Kumar, R., Ramanunny, A. K., Awasthi, A., & Dua, K. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172625 · Cited by 239
Deacon, C. F., Mannucci, E., & Ahrén, B. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01603.x · Cited by 190
The evolving place of incretin-based therapies in type 2 diabetes
Gallwitz, B. (2010) · Pediatric Nephrology · doi:10.1007/s00467-009-1435-z · Cited by 42
Metadata
- Authors
- Ahren, B.
- Venue
- Vascular Health and Risk Management
- Publisher
- Informa UK Limited
- Published
- 2008-04
- Volume
- Volume 4
- Issue
- 2
- Pages
- 383-394
- ISSN
- 1176-6344 (ISSN-L)
- 1178-2048
- OpenAlex
- W2147774754
- Cited by
- 83
- References
- 20
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.